White House Withdraws Heidi Overton’s FDA Nomination Amid Senate Fractures

3 min read
Source: AP News
White House Withdraws Heidi Overton’s FDA Nomination Amid Senate Fractures
Photo: AP News
TL;DR

The White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration (FDA) on Tuesday, hours before a scheduled Senate committee vote. Overton, a physician and domestic policy adviser, lacked the necessary Republican support to advance. Her candidacy faced opposition from moderate Republicans over vaccine and vaping policies, as well as from Democrats and pro-life groups over her anti-abortion stance. The FDA will remain under acting leadership, with Republicans unlikely to confirm a permanent commissioner before Democrats take control of the Senate in January.

Key points

  • The White House pulled Dr. Heidi Overton’s nomination for FDA commissioner on Tuesday, citing insufficient support for Senate confirmation.
  • Overton faced bipartisan scrutiny, including concerns from Republican Sen. Bill Cassidy about her stance on combination vaccines and from Sen. Susan Collins regarding flavored e-cigarettes.
  • Anti-abortion Republicans opposed her nomination over the administration’s handling of mifepristone, while pro-life groups demanded commitments on 'life issues' that the White House refused to make.
  • The FDA remains under acting leadership by Kyle Diamantas, with no clear timeline for a new nominee before Republicans lose Senate control in January.
  • Overton’s withdrawal follows the collapse of other health nominations, including those for the CDC and surgeon general, due to similar Republican opposition.

Background

Overton was nominated in August as a stabilizing figure for the FDA after a turbulent year under Dr. Marty Makary. Her nomination exposed deep divisions within the Trump administration, particularly between the 'Make America Healthy Again' movement led by HHS Secretary Robert F. Kennedy Jr. and traditional conservative circles. Previous archive coverage noted Cassidy’s indecision and the narrow window for confirmation before the Democratic Senate takeover in January.

How outlets are covering it

AP News emphasizes the bipartisan nature of the opposition, highlighting Cassidy’s final support for Overton and the role of abortion-related disagreements. CNN focuses on the internal rifts between Overton and Kennedy, describing their relationship as 'icy' and noting the influence of the 'Make America Healthy Again' movement. The Guardian, while covering the FDA story, also highlights the broader political context of the Alaska Senate race and other Trump administration controversies, but does not provide additional details on the Overton nomination itself. The sources agree on the withdrawal but differ in emphasis: AP stresses the bipartisan opposition, while CNN highlights the internal administration conflicts and the 'MAHA' movement's role.

Why it matters

The withdrawal of Overton’s nomination underscores the fragility of the Trump administration’s health policy agenda and the challenges of confirming nominees in a polarized Senate. It leaves the FDA without a permanent leader, potentially impacting regulatory decisions on vaccines, mifepristone, and other health issues. The episode also highlights the growing tensions within the Republican Party over health policy and the administration’s ability to navigate internal divisions.

What to watch

The White House has not announced a new nominee for FDA commissioner. Republicans are unlikely to confirm a permanent leader before Democrats take control of the Senate in January. The FDA will continue under acting leadership by Kyle Diamantas, with a safety review of mifepristone expected to conclude by March. The administration may face further challenges in confirming other health nominees, as seen with the CDC and surgeon general positions.

Share this article

Want the full story? Read the original reporting

Read on AP News